A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization
- PMID: 30358422
- DOI: 10.1089/cap.2018.0036
A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization
Abstract
Objectives: Clozapine is the drug of choice for treatment-resistant schizophrenia. While pediatric clozapine use is not contraindicated, the literature describing its clinical application is limited. The primary objective of this study was to assess the use of clozapine in a child and adolescent population by characterizing the documented safety and clinical benefits of the medication.
Methods: A multicenter retrospective study at sites in the United States and Australia included children and adolescents admitted to a psychiatric unit who were administered at least one dose of clozapine. Information related to demographics, patient history, past treatments, clozapine, and adverse events was collected.
Results: Eighty-two patients from eight sites were included in this study. Patients were predominantly clozapine naive (76.8%), and most had a discharge diagnosis of a primary psychotic disorder (61%) or bipolar disorder (25.6%). Four clozapine discontinuations occurred during hospitalization due to severe neutropenia, ileus, need for diagnostic clarification, and significant psychomotor retardation. The remainder (n = 78) were discharged on a mean clozapine dose of 218.1 ± 142.2 mg. Sedation (26.8%) and sialorrhea (17.1%) were the most common documented adverse events. The mean number of previously trialed antipsychotics before clozapine was 3.5 ± 1.4 (range 1-10). Improvement with clozapine was documented as significant (31.7%), moderate (32.9%), minimal (12.2%), no improvement (2.4%), and not described (20.7%).
Conclusions: In this cohort, 95% of pediatric patients admitted with or started on clozapine during an acute psychiatric hospitalization were discharged on the medication. The high incidence of adverse events should reinforce to clinicians the need for vigilant monitoring. Pediatric guidelines recommend clozapine for refractory schizophrenia but stress the critical need to ensure an accurate diagnosis. Limited data exist for the use of clozapine in pediatric patients with other diagnoses.
Keywords: bipolar disorder; clozapine; early-onset schizophrenia; pediatric; schizophrenia.
Similar articles
-
A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey.J Child Adolesc Psychopharmacol. 2016 Nov;26(9):815-821. doi: 10.1089/cap.2015.0020. Epub 2016 Jan 15. J Child Adolesc Psychopharmacol. 2016. PMID: 26771824
-
Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.J Clin Psychiatry. 2003 Apr;64(4):451-8. doi: 10.4088/jcp.v64n0416. J Clin Psychiatry. 2003. PMID: 12716249 Clinical Trial.
-
[Clozapine-induced parotitis: a case study].Encephale. 2014 Feb;40(1):81-5. doi: 10.1016/j.encep.2013.04.006. Epub 2013 Jun 27. Encephale. 2014. PMID: 23809173 French.
-
[Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].Encephale. 2016 Aug;42(4):346-53. doi: 10.1016/j.encep.2016.03.005. Epub 2016 Apr 21. Encephale. 2016. PMID: 27109327 Review. French.
-
Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.CNS Drugs. 2007;21(2):117-27. doi: 10.2165/00023210-200721020-00003. CNS Drugs. 2007. PMID: 17284094 Review.
Cited by
-
Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study.Front Psychiatry. 2020 Mar 24;11:152. doi: 10.3389/fpsyt.2020.00152. eCollection 2020. Front Psychiatry. 2020. PMID: 32265749 Free PMC article.
-
CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.BMC Psychiatry. 2024 Feb 14;24(1):122. doi: 10.1186/s12888-023-05397-1. BMC Psychiatry. 2024. PMID: 38355533 Free PMC article.
-
Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.Brain Sci. 2020 Nov 11;10(11):840. doi: 10.3390/brainsci10110840. Brain Sci. 2020. PMID: 33187329 Free PMC article. Review.
-
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.J Clin Psychopharmacol. 2025 May-Jun 01;45(3):197-218. doi: 10.1097/JCP.0000000000001990. Epub 2025 Apr 9. J Clin Psychopharmacol. 2025. PMID: 40198784 Free PMC article.
-
Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data.Eur Child Adolesc Psychiatry. 2025 Jul;34(7):2083-2091. doi: 10.1007/s00787-024-02623-3. Epub 2024 Dec 2. Eur Child Adolesc Psychiatry. 2025. PMID: 39621136
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous